Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $41.00 Consensus Price Target from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $41.00.

A number of equities research analysts have weighed in on OLMA shares. HC Wainwright lifted their price objective on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. UBS Group initiated coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a “buy” rating and a $45.00 price objective for the company. Piper Sandler began coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective for the company. Finally, The Goldman Sachs Group upped their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, December 11th.

Insider Activity

In other news, Director Ian T. Clark sold 264,800 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $29.73, for a total value of $7,872,504.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Naseem Zojwalla sold 99,509 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total value of $2,752,418.94. Following the sale, the insider owned 4,488 shares in the company, valued at approximately $124,138.08. This trade represents a 95.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 648,190 shares of company stock valued at $18,701,978 over the last three months. 16.36% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd increased its stake in shares of Olema Pharmaceuticals by 153.8% in the second quarter. Persistent Asset Partners Ltd now owns 58,333 shares of the company’s stock valued at $248,000 after buying an additional 35,345 shares in the last quarter. Titleist Asset Management LLC acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth about $64,000. Diadema Partners LP grew its holdings in Olema Pharmaceuticals by 153.7% during the 2nd quarter. Diadema Partners LP now owns 253,657 shares of the company’s stock worth $1,081,000 after acquiring an additional 153,657 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock valued at $2,787,000 after acquiring an additional 358,412 shares in the last quarter. Finally, Birchview Capital LP bought a new position in shares of Olema Pharmaceuticals in the second quarter worth about $571,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Up 3.2%

Shares of OLMA stock opened at $28.77 on Monday. The stock has a market cap of $1.98 billion, a P/E ratio of -15.38 and a beta of 1.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The stock has a fifty day moving average price of $24.28 and a 200 day moving average price of $13.00. Olema Pharmaceuticals has a one year low of $2.86 and a one year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Analysts predict that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.